Essential Partners’s Neuropace NPCE Stock Holding History

Essential Partners’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-4	Closed	-$64	–	2954
2026 Q2	$64	Sell	4 -27	-87%	-$435	﹤0.01%	2778
2026 Q1	$408	Buy	+31	New	+$465	﹤0.01%	2493

Other funds holding NPCE

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's NPCE Position: Q3 2026 in Review

Essential Partners sold out of Neuropace (NPCE) in Q3 2026, closing a stake of 4 shares — an estimated $64 sold.

Essential Partners first reported a position in NPCE in Q1 2026 and held it in 2 quarters. The position peaked at $408 in Q1 2026. 7 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

Essential Partners reported no remaining Neuropace position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 4 Neuropace shares in Q3 2026, an estimated $64.
Essential Partners first reported a position in Neuropace in Q1 2026 and held it in 2 quarters.
Essential Partners's Neuropace position peaked at $408 in Q1 2026.
7 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.